Next-Generation Immunotherapy for NMIBC: QUILT 2.005 and QUILT 3.032

Dr. Patrick Soon-Shiong, Executive Chairman of ImmunityBio, provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept (Anktiva) for non-muscle invasive bladder cancer presented at the AUA 2024 Annual Meeting.
Dr. Soon-Shiong shares how the IL-15 agonist agent works, the next line of research for the immunoagent now that the FDA has approved it for BCG-unresponsive patients with NMIBC, and how ImmunityBio is addressing the worldwide BCG shortage.

[@mattquistorf]

This is incredible news! Thanks for sharing this information about PSS and Anktiva.

[@fatmirdermyshi9866]

$ibrx to the moon

[@user-sg4zu4bo2c]

Wow.